260 related articles for article (PubMed ID: 26961176)
1. Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A.
Pelillo C; Mollica H; Eble JA; Grosche J; Herzog L; Codan B; Sava G; Bergamo A
J Inorg Biochem; 2016 Jul; 160():225-35. PubMed ID: 26961176
[TBL] [Abstract][Full Text] [Related]
2. Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A.
Bergamo A; Pelillo C; Chambery A; Sava G
J Inorg Biochem; 2017 Mar; 168():90-97. PubMed ID: 28064102
[TBL] [Abstract][Full Text] [Related]
3. Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.
Brescacin L; Masi A; Sava G; Bergamo A
J Biol Inorg Chem; 2015 Oct; 20(7):1163-73. PubMed ID: 26369538
[TBL] [Abstract][Full Text] [Related]
4. Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin.
Pelillo C; Bergamo A; Mollica H; Bestagno M; Sava G
J Cell Biochem; 2015 Oct; 116(10):2385-96. PubMed ID: 25857463
[TBL] [Abstract][Full Text] [Related]
5. Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A.
Sava G; Frausin F; Cocchietto M; Vita F; Podda E; Spessotto P; Furlani A; Scarcia V; Zabucchi G
Eur J Cancer; 2004 Jun; 40(9):1383-96. PubMed ID: 15177498
[TBL] [Abstract][Full Text] [Related]
6. Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.
Novohradský V; Bergamo A; Cocchietto M; Zajac J; Brabec V; Mestroni G; Sava G
Dalton Trans; 2015 Jan; 44(4):1905-13. PubMed ID: 25489765
[TBL] [Abstract][Full Text] [Related]
7. TGFbeta1 regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumours.
Casarsa C; Mischis MT; Sava G
J Inorg Biochem; 2004 Oct; 98(10):1648-54. PubMed ID: 15458828
[TBL] [Abstract][Full Text] [Related]
8. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
[TBL] [Abstract][Full Text] [Related]
9. Ruthenium antimetastatic agents.
Alessio E; Mestroni G; Bergamo A; Sava G
Curr Top Med Chem; 2004; 4(15):1525-35. PubMed ID: 15579094
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues.
Oszajca M; Collet G; Stochel G; Kieda C; Brindell M
Biometals; 2016 Dec; 29(6):1035-1046. PubMed ID: 27812766
[TBL] [Abstract][Full Text] [Related]
11. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.
Bacac M; Hotze AC; van der Schilden K; Haasnoot JG; Pacor S; Alessio E; Sava G; Reedijk J
J Inorg Biochem; 2004 Feb; 98(2):402-12. PubMed ID: 14729322
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.
Gava B; Zorzet S; Spessotto P; Cocchietto M; Sava G
J Pharmacol Exp Ther; 2006 Apr; 317(1):284-91. PubMed ID: 16368900
[TBL] [Abstract][Full Text] [Related]
13. CDK1 hyperphosphorylation maintenance drives the time-course of G2-M cell cycle arrest after short treatment with NAMI-A in Kb cells.
Bergamo A; Delfino R; Casarsa C; Sava G
Anticancer Agents Med Chem; 2012 Oct; 12(8):949-58. PubMed ID: 22263785
[TBL] [Abstract][Full Text] [Related]
14. The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway.
Sanna B; Debidda M; Pintus G; Tadolini B; Posadino AM; Bennardini F; Sava G; Ventura C
Arch Biochem Biophys; 2002 Jul; 403(2):209-18. PubMed ID: 12139970
[TBL] [Abstract][Full Text] [Related]
15. Single cell tracking assay reveals an opposite effect of selective small non-peptidic α5β1 or αvβ3/β5 integrin antagonists in U87MG glioma cells.
Ray AM; Schaffner F; Janouskova H; Noulet F; Rognan D; Lelong-Rebel I; Choulier L; Blandin AF; Lehmann M; Martin S; Kapp T; Neubauer S; Rechenmacher F; Kessler H; Dontenwill M
Biochim Biophys Acta; 2014 Sep; 1840(9):2978-87. PubMed ID: 24810979
[TBL] [Abstract][Full Text] [Related]
16. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
[TBL] [Abstract][Full Text] [Related]
17. Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro.
Hostetter AA; Miranda ML; DeRose VJ; McFarlane Holman KL
J Biol Inorg Chem; 2011 Dec; 16(8):1177-85. PubMed ID: 21739255
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex.
Sava G; Capozzi I; Clerici K; Gagliardi G; Alessio E; Mestroni G
Clin Exp Metastasis; 1998 May; 16(4):371-9. PubMed ID: 9626816
[TBL] [Abstract][Full Text] [Related]
19. Comparison of KP1019 and NAMI-A in tumour-mimetic environments.
Gransbury GK; Kappen P; Glover CJ; Hughes JN; Levina A; Lay PA; Musgrave IF; Harris HH
Metallomics; 2016 Aug; 8(8):762-73. PubMed ID: 27460862
[TBL] [Abstract][Full Text] [Related]
20. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
Bergamo A; Gava B; Alessio E; Mestroni G; Serli B; Cocchietto M; Zorzet S; Sava G
Int J Oncol; 2002 Dec; 21(6):1331-8. PubMed ID: 12429985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
